Keros Therapeutics (KROS) AI Stock Analysis

• Market Cap: $665.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): 14.1
• Beta (1Y): 0.58
• Revenue Growth: 37798.31%
• EPS Growth: N/A
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 30,466,068
• 10 Day Avg. Volume: 899,686
• 30 Day Avg. Volume: 1,179,132
• PEG Ratio: 0.82
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 166.94
• P/FCF Ratio: -3.64
• Enterprise Value/Market Cap: -0.05
• Enterprise Value/Revenue: -0.14
• Enterprise Value/Gross Profit: -0.14
• Enterprise Value/Ebitda: -0.41
• 1Y Price Target: $21.00
• Price Target Upside: -3.18% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 1.9
• Revenue Forecast (FY): $244.16M

• Rating: 72 Outperform
• Price Target: $23.50 ▲(8.34% Upside)

Keros Therapeutics receives a strong score due to its positive financial performance and strategic corporate actions. The company's robust technical indicators and reasonable valuation further support the stock's attractiveness. However, overbought technical signals and historical financial volatility warrant cautious optimism.

Positive Factors

Strong Balance Sheet

A strong balance sheet with low leverage enhances financial stability and provides flexibility for strategic investments and R&D.

Improved Profitability

Improved profitability indicates effective cost management and operational efficiency, supporting sustainable growth and investment capacity.

Capital Return Program

The capital return program reflects confidence in financial health and aims to enhance shareholder value, supporting long-term investor trust.

Negative Factors

Revenue Volatility

Revenue volatility can challenge long-term planning and stability, potentially impacting investor confidence and strategic decision-making.

Cash Flow Volatility

Volatile cash flows may affect the company's ability to fund operations and strategic initiatives, posing risks to financial health.

Board Changes

Frequent board changes can lead to strategic uncertainty and may disrupt long-term planning and governance stability.

Keros Therapeutics Business Overview & Revenue Model

Company Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

Keros Therapeutics generates revenue primarily through the development and eventual commercialization of its therapeutic candidates. The company does not currently have products on the market; however, it aims to monetize its pipeline through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. Additionally, Keros may receive milestone payments and royalties based on the performance of its products once they are commercialized. The company also funds its operations through equity financing and grants, which support its research and development activities.

Keros Therapeutics Financial Statement Overview

Summary

Keros Therapeutics shows a positive financial trajectory with improved profitability and strong balance sheet metrics. The company has effectively managed costs and leverage, resulting in better margins and financial stability. However, historical volatility in revenue and cash flows suggests the need for cautious optimism moving forward.

Income Statement

Keros Therapeutics has shown a significant improvement in its income statement metrics over the TTM period. The gross profit margin is exceptionally high at 99.56%, indicating strong cost management. The net profit margin has turned positive at 8.06%, a significant improvement from previous negative margins, reflecting better profitability. Revenue growth rate of 5.96% in the TTM suggests a positive trajectory, although the company has experienced volatility in revenue growth in prior years.

Balance Sheet

The balance sheet of Keros Therapeutics is strong, with a low debt-to-equity ratio of 0.025, indicating minimal leverage and financial risk. The return on equity (ROE) is modest at 2.96%, showing a positive return to shareholders. The equity ratio is healthy, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

The cash flow statement shows a robust free cash flow growth rate of 64.06% in the TTM, indicating improved cash generation. The operating cash flow to net income ratio is 1.59, suggesting strong cash conversion. However, historical cash flow volatility and negative cash flows in prior years highlight potential risks in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	246.72M	3.55M	151.00K	0.00	20.10M	0.00
Gross Profit	245.62M	3.55M	151.00K	0.00	20.10M	-605.00K
EBITDA	82.39M	-185.82M	-152.18M	-104.00M	-56.35M	-44.92M
Net Income	64.45M	-187.35M	-152.99M	-104.68M	-58.74M	-45.36M
Balance Sheet
Total Assets	742.78M	615.89M	370.02M	306.78M	255.25M	269.44M
Cash, Cash Equivalents and Short-Term Investments	693.47M	559.93M	331.15M	279.05M	230.04M	265.88M
Total Debt	17.43M	18.86M	14.44M	13.27M	1.09M	899.00K
Total Liabilities	39.20M	44.33M	37.81M	29.36M	12.08M	7.72M
Stockholders Equity	703.58M	571.55M	332.21M	277.42M	243.17M	261.72M
Cash Flow
Free Cash Flow	87.08M	-162.80M	-126.97M	-71.30M	-63.17M	-37.19M
Operating Cash Flow	88.79M	-160.87M	-124.51M	-70.06M	-62.15M	-36.89M
Investing Cash Flow	-1.71M	-1.93M	-2.46M	-1.24M	-1.02M	-294.00K
Financing Cash Flow	75.70M	391.82M	178.96M	120.31M	28.55M	296.04M

Keros Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Positive. The current price of 21.69 is above the 20-day moving average (MA) of 18.52, above the 50-day MA of 16.71, and above the 200-day MA of 14.47, indicating a bullish trend. The MACD of 1.42 indicates Negative momentum. The RSI at 76.43 is Negative, neither overbought nor oversold. The STOCH value of 85.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KROS.

Keros Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	72 Outperform	$665.38M	14.06	10.43%	―	37798.31%	―
GYRE	64 Neutral	$768.74M	209.45	8.06%	―	―	―
NRIX	54 Neutral	$1.99B	―	-65.35%	―	48.32%	-1.91%
PVLA	52 Neutral	$1.11B	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCAX	48 Neutral	$1.03B	―	-26.64%	―	―	―
KALV	45 Neutral	$816.83M	―	―	―	―	-13.14%

Keros Therapeutics Corporate Events

Keros Therapeutics Announces $375M Capital Return Program

On October 15, 2025, Keros Therapeutics announced a $375 million capital return program, including repurchasing shares from ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million. This move, alongside a planned tender offer for additional shares, reflects Keros’ confidence in its financial position and clinical strategy, particularly for its KER-065 program. The resignations of board members Tomer Kariv and Ran Nussbaum were also announced, with Jean-Jacques Bienaimé appointed as the new Chair of the Nominating and Corporate Governance Committee. The company plans to distribute part of its Takeda licensing revenue to shareholders, aiming to enhance long-term stockholder value.